Form 8-K - Current report:
SEC Accession No. 0001213900-25-036109
Filing Date
2025-04-28
Accepted
2025-04-28 16:30:31
Documents
15
Period of Report
2025-04-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0239800-8k_oramed.htm   iXBRL 8-K 34175
2 FORM OF SHARE PURCHASE AGREEMENT, DATED AS OF APRIL 28, 2025, BY AND BETWEEN ORA ea023980001ex10-1_oramed.htm EX-10.1 157827
3 PRESS RELEASE, DATED APRIL 28, 2025 (FURNISHED PURSUANT TO ITEM 7.01) ea023980001ex99-1_oramed.htm EX-99.1 8590
  Complete submission text file 0001213900-25-036109.txt   425384

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ormp-20250424.xsd EX-101.SCH 3008
5 XBRL LABEL FILE ormp-20250424_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE ormp-20250424_pre.xml EX-101.PRE 22354
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0239800-8k_oramed_htm.xml XML 3688
Mailing Address 1185 AVENUE OF THE AMERICAS, 3RD FLOOR NEW YORK NY 10036
Business Address 1185 AVENUE OF THE AMERICAS, 3RD FLOOR NEW YORK NY 10036 646-844-1164
ORAMED PHARMACEUTICALS INC. (Filer) CIK: 0001176309 (see all company filings)

EIN.: 980376008 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35813 | Film No.: 25880853
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)